Sodium-Glucose Cotransporter 2 Inhibitors for T2DMSodium-Glucose Cotransporter 2 Inhibitors for T2DM
Learn about the new sodium-glucose cotransporter 2 inhibitors canagliflozin and dapagliflozin in this overview, including their benefits, adverse effects, and potential place in therapy. Southern Medical Journal
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
More News: Dapagliflozin | Diabetes | Endocrinology | Forxiga | Health | Learning | Universities & Medical Training